Polaryx Therapeutics, Inc. Common Stock (PLYX)

Polaryx Therapeutics, Inc. Common Stock (PLYX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $98.2M; returns 1 day -4.6%, 1 week -1.6%.

Polaryx Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders (LSDs). As of February 2026, the company is pre-revenue, with its economic value driven entirely by its clinical pipeline.

Groups PLYX belongs to

• Clinical Stage Biotech
• Recent IPOs
• Rare Diseases
• Biotechnology
• Clinical Stage
• Biopharmaceutical
• Neuroscience
• 505(b)(2) Pathway
• Neurological Disorders
• Healthcare
• Gene Therapy

PLYX financial model: income statement, cash flow and balance sheet